Previously, we identified CXCL4 in pDCs as an early biomarker for Systemic sclerosis (SSc), an archetypical fibrotic disease in which endothelial cell damage and immune activation typically culminates in inflammation and fibrosis of the skin and internal organs (7). Here, PF4 is linked to systemic sclerosis.